Loading organizations...
SARcode Bioscience is a technology company.
SARcode Bioscience developed small molecule lymphocyte function-associated antigen-1 antagonists, notably lifitegrast ophthalmic solution for dry eye disease. Their technical approach focused on modulating specific immunological pathways to address chronic inflammatory conditions, initially in ophthalmology. The company specialized in creating novel small-molecule therapies for targeted biological intervention.
Established in 2006, SARcode Bioscience originated from the insight that targeted immunomodulation could offer significant therapeutic benefits for unmet medical needs. While founder details are not publicly emphasized, the company was built to translate biological understanding into impactful treatments, driven by a commitment to ophthalmic innovation.
SARcode aimed to deliver effective, targeted treatments for patients with chronic inflammatory conditions, particularly dry eye. The company’s vision was to enhance quality of life through innovative pharmaceutical development, providing solutions for diseases with limited prior options. Their strategy involved broadening therapeutic scope to address a wider array of inflammatory indications.
SARcode Bioscience has raised $44.0M across 1 funding round.
SARcode Bioscience has raised $44.0M in total across 1 funding round.
SARcode Bioscience has raised $44.0M in total across 1 funding round.
SARcode Bioscience's investors include HealthQuest Capital.
SARcode Bioscience was a private biopharmaceutical company based in San Francisco (with operations in Brisbane, California) focused on developing small molecule LFA-1 antagonists and lymphocyte function-associated antigen-1 inhibitors to treat inflammatory diseases, particularly in ophthalmology and dermatology.[1][2][3][4] Its lead product, lifitegrast (under phase 3 trials at acquisition for dry eye disease signs and symptoms), targeted T-cell mediated conditions like dry eye, diabetic retinopathy, eczema, and psoriasis, addressing unmet needs in these areas by modulating immune responses.[1][3][4] The company served patients with inflammatory eye and skin disorders through topical therapies and was acquired by Shire plc in March 2013 for $160 million, integrating its pipeline into Shire's ophthalmology portfolio.[1][4][5]
SARcode Bioscience emerged as a biotechnology venture specializing in novel small molecule therapies for immunology-related diseases, though specific founders and exact founding year are not detailed in available records.[1][2] The idea stemmed from advancing LFA-1 antagonists—molecules that inhibit leukocyte function-associated antigen-1 to curb excessive immune activity in conditions like dry eye and psoriasis—building early traction through clinical progression to phase 3 trials for lifitegrast.[1][4] A pivotal moment came with positive FDA feedback on initial trial data (OPUS-1), enabling ongoing studies like OPUS-2 (efficacy) and SONATA (safety), which positioned it for acquisition by Shire in 2013 amid growing demand for ophthalmology innovations.[4][5]
SARcode rode the early 2010s wave of targeted immunomodulation therapies, capitalizing on advances in understanding leukocyte overactivity in chronic inflammatory diseases like dry eye—a market with significant unmet needs due to limited topical options.[1][4] Timing aligned with rising ophthalmology investments, as Shire expanded via acquisitions like SARcode and Premacure to build a specialist portfolio amid projected growth in eye care therapeutics.[4][5] It influenced the ecosystem by validating LFA-1 inhibition, paving the way for integrated big-pharma pipelines and competitors like NGM Biopharmaceuticals and Osprey Pharmaceuticals in biologics and leukocyte modulation.[1]
Post-2013 acquisition, SARcode's assets transitioned fully into Shire (later Takeda), with lifitegrast approved as Xiidra for dry eye, establishing a commercial foothold before facing market competition and eventual discontinuation around 2023.[1][4] Future trends like AI-driven drug discovery and next-gen biologics may eclipse its small-molecule approach, but its legacy endures in shaping ophthalmology R&D. As biotech consolidation continues, SARcode exemplifies how innovative pipelines attract acquirers, fueling broader advancements in immune-targeted therapies for inflammatory diseases.[1][4]
SARcode Bioscience has raised $44.0M across 1 funding round. Most recently, it raised $44.0M Series B in July 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2011 | $44.0M Series B | HealthQuest Capital |